Market revenue in 2023 | USD 306.9 million |
Market revenue in 2030 | USD 698.0 million |
Growth rate | 12.5% (CAGR from 2023 to 2030) |
Largest segment | Serum-free media |
Fastest growing segment | Serum-free Media |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum-free Media, Classical Media, Stem Cell Culture Media, Chemically Defined Media, Specialty Media, Other Cell Culture Media |
Key market players worldwide | Sartorius AG, Danaher Corp, Merck KGaA, Thermo Fisher Scientific Inc, FUJIFILM Holdings Corp, Lonza Group Ltd, BD, STEMCELL Technologies, PromoCell GmbH |
Serum-free media was the largest segment with a revenue share of 38.35% in 2023. Horizon Databook has segmented the Canada cell culture media market based on serum-free media, classical media, stem cell culture media, chemically defined media, specialty media, other cell culture media covering the revenue growth of each sub-segment from 2018 to 2030.
Canada's regulatory approach involves three sets of regulations, namely the Cells, Tissues and Organs Regulations; the Food and Drug Regulations; and the Medical Devices Regulations. In Canada, CGT products are regulated under the existing regulatory frameworks developed for pharmaceutical & biologic drugs, human material for transplants, and medical devices.
A majority of CGTs are classified as biologics and are regulated by the Biologic and Radiopharmaceutical Drugs Directorate (BRDD) within Health Canada. As a biological drug, the sponsor of a CGT must submit a Clinical Trial Application (CTA) to Health Canada prior to commencing a clinical trial, and file a New Drug Submission (NDS) for review and approval prior to marketing a new therapy in Canada.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account